Precise Insights

Advanced Data and AI for Melanoma

On-demand access to the largest and most sophisticated oncology data for accelerated RWE and improved patient outcomes.

See some of the 1000s of data elements we offer:

Structured Fields

Request a Demo

 

labs

Results from variety of patient tests

Visits

Oncology practice visits

Observations

Tumor-related observations plus vitals, biometrics, pain, and more

Procedures

Surgeries, radiation, biopsies, imaging, chemotherapy, etc

Medications

Start and end dates, brand vs. generic codes, dosage, duration, and cycles

Diagnoses

Disease state, status, severity, and metastasis

Expert Abstraction

Request a Demo

 

Biomarkers

Biomarker testing, results, and timing

Disease Progression

Directly-observed measures of critical endpoints

Adverse Events

Different types of adverse responses

Histology

Classification into multiple categories

Enriched Data

Request a Demo

 

Cost & Utilization

Adjudicated costs with linked claims data

Safety, Comorbidities

Pre-cancer and claims charge events

Specialty Pharmacy & Hub

Rx acquisition status details

Payer & Formulary

Drug tiers and coverage

Social Determinants

Social and physical environment factors

AI-Enriched Insights

Request a Demo

 

Date of Metastasis

Rules-based imputation of date of metastasis

Metastatic Status

Imputation of missing data from unstructured notes

Date of Initial Dx

Imputation of index event

Line of Therapy

Regimen or progression-based drug classes

Patient Adherence

Identify root cause of product switching

Patient Acquisition

Predict factors driving patients’ brand decision

Request Data Count

Explore ConcertAI datasets to see how many patients are in your disease area and meet study criteria.

melanoma

Research Studies

Our scientists regularly publish leading RWE studies in the fields of clinical development and health economics and outcomes research.

melanoma research study

Burden of Illness of Adjuvant Therapy for Advanced Melanoma

Stage I-III melanoma at high risk of progression is treated with the approved systemic adjuvant therapy. This study described treatment patterns, clinical outcomes, and healthcare costs among these patients.

See Full Study
Methods

Retrospective Observational Study

Patient Criteria
  • Adult patients with Stage I-III melanoma
  • Diagnosed between 1/2007 and 4/2013
  • Treated or untreated with systemic adjuvant therapy
Results

636

Eligible patients

Findings:

0

Patients treated with adjuvant systemic therapy

0

Received interferon/peginterferon therapy

Costs
$0

Median cost of interferon/peginterferon therapy


$0

Total Cost

Findings:

0

Months patients were treated with interferon

0%

Patients remained on therapy at 1 year

Conclusion

Real-world patients are older and sicker than those enrolled in pivotal clinical trials. Application of clinical trial findings to dissimilar populations may result in patient harm.

Value in Health, 2015

Request a Demo